KRISHAN GUPTA: Open Payments
NPI 1598769176 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$816 in 50 payments from 12 companies in 2025. Trend: 2023 $956 · 2024 $628 · 2025 $816
Food & beverage: $816
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 13 | $195 |
| Tris Pharma Inc | 8 | $140 |
| ABBVIE INC. | 10 | $136 |
| Otsuka America Pharmaceutical, Inc. | 5 | $84 |
| Supernus Pharmaceuticals, Inc. | 5 | $78 |
| MEDICOMP INC | 1 | $40 |
| Neurocrine BioSciences, Inc. | 2 | $36 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| Indivior Inc. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $19 |
Products named: FANAPT, VRAYLAR, Dyanavel XR, Qelbree, REXULTI, TELEPATCH CARDIAC MONITOR, Onyda XR, INGREZZA.
Industry payments across MS — which companies pay providers there.
